Today: 1 May 2026
AMD stock falls 2.5% as tech retreats, Feb. 3 earnings and CES AI chips in focus

AMD stock falls 2.5% as tech retreats, Feb. 3 earnings and CES AI chips in focus

New York, January 8, 2026, 18:12 EST — Market closed

  • AMD shares fell 2.5% to $204.68, in line with a pullback across AI-linked tech.
  • CES chip unveilings kept focus on AMD’s bid to take share from Nvidia in data-center accelerators.
  • AMD is set to report results on Feb. 3 after the market close.

Shares of Advanced Micro Devices fell 2.5% in after-hours trading on Thursday, closing at $204.68. The drop unfolded against a backdrop of some choppiness in the wider market.

The drop stands out as investors turn pickier on the AI trade just before earnings season kicks off. For AMD, the focus isn’t only on flashy new hardware launches—it’s whether those wins translate into tangible shipments and better profit margins.

AMD said on Tuesday it will release its fiscal fourth-quarter and full-year 2025 earnings on Feb. 3, right after the market closes. A conference call is scheduled for 5 p.m. EST that same day. Meanwhile, the company revealed that its chief technology officer, Mark Papermaster, will speak at Morgan Stanley’s Technology, Media & Telecom Conference on March 3.

Wall Street wrapped up mixed, with some tech giants taking a hit—Nvidia fell 2.2%, Broadcom slid 3.2%. The Nasdaq dipped 0.44%, according to Reuters. “While AI is still hot, there are going to be winners and losers,” said Art Hogan, chief market strategist at B. Riley Wealth, calling it a “show me” sector. Reuters

At CES in Las Vegas on Monday, CEO Lisa Su put AMD’s MI455 processors in the spotlight, showing how they power server racks for clients like OpenAI. She also introduced the MI440X — an “enterprise” chip designed for on-premise setups, aiming straight at companies’ own data centers instead of specialized AI clusters. Reuters reported that AMD’s October deal with OpenAI could add billions to its annual revenue, with the first MI400-based systems expected to hit the market this year; OpenAI President Greg Brockman stressed that upgrading chips was crucial to handle its “vast computing needs.” Reuters

The Philadelphia Semiconductor Index fell around 1.8% on Thursday, underscoring the persistent struggles facing chip stocks.

Treasury yields edged higher, with eyes fixed on Friday’s key U.S. jobs report. The numbers might jolt interest-rate forecasts and shift the way investors price growth stocks.

But AMD has a tricky path ahead: it needs to ramp up accelerator sales without cutting prices or trimming margins. At the same time, Nvidia is working flat out to keep up with demand. If the hype around AI cools off, sentiment in the market could shift just as fast.

Investors are zeroing in on AMD’s Feb. 3 earnings report, searching for signs about data-center accelerator shipments and whether demand will hold firm through 2026. Then, all attention turns to March 3, when Papermaster is scheduled to speak at Morgan Stanley’s conference.

Stock Market Today

  • Avalyn Pharma upsizes IPO to $300 million, Alector halts study with GSK
    May 1, 2026, 12:10 AM EDT. Avalyn Pharma, a Boston-based biotech, is raising $300 million by selling 16.5 million shares at $18 each in an upsized initial public offering (IPO). The capital raise aims to fund its drug development programs. Separately, Alector, in partnership with GlaxoSmithKline (GSK), has terminated another clinical study, though further details remain limited. These moves reflect ongoing volatility and strategic shifts within the biotech sector as firms adjust pipelines and capital strategies amid challenging market conditions.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 01.05.2026

1 May 2026
LIVEMarkets rolling coverageStarted: May 1, 2026, 12:00 AM EDTUpdated: May 1, 2026, 12:13 AM EDT Avalyn Pharma upsizes IPO to $300 million, Alector halts study with GSK May 1, 2026, 12:10 AM EDT. Avalyn Pharma, a Boston-based biotech, is raising $300 million by selling 16.5 million shares at $18 each in an upsized initial public offering (IPO). The capital raise aims to fund its drug development programs. Separately, Alector, in partnership with GlaxoSmithKline (GSK), has terminated another clinical study, though further details remain limited. These moves reflect ongoing volatility and strategic shifts within the biotech sector as firms adjust pipelines
Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

Sandisk Stock Falls After Blowout Q3 Earnings as AI Storage Rally Hits a High Bar

1 May 2026
Sandisk shares dropped about 6% in after-hours trading Thursday despite reporting fiscal Q3 revenue of $5.95 billion, up 251% from a year earlier, and net income of $3.62 billion. The company announced a $6 billion buyback and forecast Q4 revenue of up to $8.25 billion. Gross margin rose to 78.4%. Shares had closed at $1,096.51 before slipping to about $1,030.
Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

Apple Stock Slips After Earnings Beat as iPhone Supply Snag Clouds $100 Billion Buyback

1 May 2026
Apple reported fiscal Q2 revenue of $111.2 billion and earnings of $2.01 per share, beating analyst estimates. The board approved a $100 billion share buyback and raised the dividend. Shares fell about 1% after hours as iPhone sales missed forecasts and chip supply remained tight. Investors are watching for clarity on AI strategy and the upcoming CEO transition to John Ternus.
Oracle stock slips as tech cools on AI spending doubts; payrolls next test
Previous Story

Oracle stock slips as tech cools on AI spending doubts; payrolls next test

Robinhood stock slips after CEO share sale; jobs report and Feb. 10 earnings set the next test
Next Story

Robinhood stock slips after CEO share sale; jobs report and Feb. 10 earnings set the next test

Go toTop